{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061992","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.276685+00:00","generated_at":"2026-06-08T07:09:37.525314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IN8bio Q3 net loss $7.2M; cash $12.9M; clinical progress on gamma-delta T cell trials","bullets":["Net loss $7.2M ($0.23/sh) vs $7.4M ($0.34/sh) in Q3 2022; R&D $3.8M, G&A $3.4M.","Cash $12.9M at Sep 30, 2023, down from $17.0M at Jun 30, 2023.","Phase 1 INB-100 dose escalation completed; ASH data presentation Dec 11, 2023.","Phase 2 INB-400 in newly diagnosed GBM enrollment initiated; SNO poster Nov 17.","Phase 1 INB-200 updated data at SNO Nov 17; Cohort 3 enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061992","json":"https://secwatch.observer/filing/0000950170-23-061992.json","markdown":"https://secwatch.observer/filing/0000950170-23-061992.md","text":"https://secwatch.observer/filing/0000950170-23-061992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/0000950170-23-061992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/inab-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:09:37.525314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f3c979a4e14bc7106ba7a61b1eddece8f80358e","claim":"IN8BIO, INC. reported the three months ended September 30, 2023 results: net income Net loss of $7.2 million, or $0.23 per basic and diluted common share, EPS $0.23 per basic and diluted common share.","evidence_excerpt":"The Company reported a net loss of $7.2 million, or $0.23 per basic and diluted common share, for the three months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/0000950170-23-061992-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Net income","value":"Net loss of $7.2 million, or $0.23 per basic and diluted common share"},{"label":"EPS","value":"$0.23 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}